Table 1. Patient characteristics.

Characteristic	No. of patients (n=232)
Median age, years (range)	62 (20 to 82)
Sex, n (%)
Male	193 (83.2)
Female	39 (16.8)
ECOG PS, n (%)
0–1	226 (97.4)
2	6 (2.6)
Smoking history, n (%)
Current/former	146 (62.9)
Never	86 (37.1)
Pathology, n (%)
Adenocarcinoma	146 (62.9)
Squamous	64 (27.6)
Others	22 (9.5)
Staging, n (%)
IIIB–IV	199 (85.8)
Post-operative recurrence	33 (14.2)
Gene aberrations, n (%)
Wild-type	190 (81.9)
Mutated	42 (18.1)
Treatment strategy, n (%)
ICI alone	128 (55.2)
ICI + chemotherapy	64 (27.6)
ICI + anti-angiogenesis	40 (17.2)
Treatment line, n (%)
First	66 (28.4)
Second	94 (40.5)
≥Third	72 (31.1)
Number of metastatic sites, n (%)
0–1	126 (54.3)
2–3	84 (36.2)
≥4	22 (9.5)
Brain metastasis, n (%)
Yes	29 (12.5)
No	203 (87.5)
Liver metastasis, n (%)
Yes	29 (12.5)
No	203 (87.5)
Bone metastasis, n (%)
Yes	87 (37.5)
No	145 (62.5)
Adrenal metastasis, n (%)
Yes	29 (12.5)
No	203 (87.5)
Pleural metastasis, n (%)
Yes	74 (31.9)
No	158 (68.1)
Contralateral lung metastasis, n (%)
Yes	113 (48.7)
No	119 (51.3)